1B20 PCSK9 antagonists
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
Merck Sharp & Dohme Corp.
A C C A C C C A C C A
A61P C12N C07K A61P C07K C07K C07K A61K C07K C07K A61P
inventional inventional additional inventional additional additional additional additional additional inventional inventional
Feng Shilpa Henryk Rose M. Holly A. Jon H. Joseph C. Kevin Heidi Laurence B. Dana D. Yan Ayesha Sonia M. Peter Jeffrey T. Timothy Denise K. Pingyu
Dong Pandit Mach Cubbon Hammond Condra Santoro Wang Yoder Peterson Wood Li Sitlani Gregory Luo Blue McCabe Nawrocki Zhong